Lutetium-177 PSMA Therapy for Advanced Prostate Cancer: Miguel’s Story

When Miguel T., a 64-year-old engineer from Barcelona, was diagnosed with metastatic prostate cancer, he thought it was the end of the road. Researching treatment options abroad led him to Acibadem Maslak Hospital in Istanbul.

“The team created a personalized plan for me. I received hormone therapy, chemotherapy, and later a cutting-edge radioactive treatment called Lutetium-177 PSMA. Every step was carefully monitored. I wasn’t just a number — I was treated like a member of the family,” Miguel says.

Lutetium-177 PSMA is a targeted nuclear-medicine therapy used for selected patients with advanced, PSMA-positive prostate cancer, typically after other treatments. It delivers radiation directly to prostate cancer cells while limiting exposure to healthy tissue, and is planned and monitored by a multidisciplinary team of oncologists and nuclear-medicine specialists.

Today, Miguel reports that his scans are clear and that he is back to spending time with his grandchildren. “I appreciate every day of my life. Thanks to the physicians, nurses and staff at Acibadem Maslak Hospital. No matter where you are in the world, there is always hope.”

Outcomes in advanced prostate cancer vary from patient to patient, and eligibility for Lu-177 PSMA therapy requires specialist imaging and assessment. Request a second opinion or a free treatment-plan review to learn whether targeted therapy fits your case — or explore our oncology treatments.